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Introduction
The theme of the congress was ‘Time to audit and look
ahead’. As with many of the major critical care meetings
this year, the arrival of a new millennium was seen as a
good opportunity to take stock of where the field of inten-
sive care medicine stands, and also to assess where we
are heading with our understanding and treatment of the
critically ill.
Genetic susceptibility to infection and sepsis
It seems obvious that there must be a genetic component
to the susceptibility of individuals to infection and also
sepsis. The key question revolves around the relevance of
any data indicating that there are indeed recognisable
genetic polymorphisms that predispose individuals to
either becoming infected, or having a disproportionate
response to a bacterial insult.
Christian Brun-Buisson (Creteil, France) elegantly demon-
strated that there are a number of clearly recognisable
genetic polymorphisms associated with infection or
sepsis. Work by Sorensen and co-workers [1] with a
cohort of adoptees showed that there was a link between
the death of the biological parents from infection and
disease and their (environmentally dissociated) offspring.
He also reported on work by Newport and co-workers [2]
and Jouanguy and co-workers [3] showing that mutations
in the interferon (IFN)g receptor 1 gene increased suscep-
tibility to microbacterial infection. Similarly Yee and co-
workers [4] showed that a polymorphism in the FcgRIIa
receptor could lead to an increased incidence of infection
from encapsulated bacteria (the receptor is of key impor-
tance in the complement activation pathway). Additional
evidence to support the case for the role of polymor-
phisms in infection and sepsis comes from work by West-
endorp and co-workers [5] showing that polymorphisms in
the plasminogen activator inhibitor (PAI-1) can be linked to
outcome in patients.
Dr Brun-Bruisson contended that a serious search for, and
study of, potential candidate polymorphisms could lead to
novel treatments and possibly some prophylactic mea-
sures to minimise either susceptibility or the effects of
infection.
Julian Bion (Birmingham, UK), whilst conceding immedi-
ately that genetic variability obviously has a role to play,
posed the following questions: Is it important? Can it be
measured? What interventions are available? The majority
of patients presenting to the intensive care unit (ICU) with
sepsis are, as a matter of course, well into the disease
process. This challenges the relevance of susceptibility in
the present day ICU, for if the knowledge of an individual’s
susceptibility is to be of any use, it is only relevant prior to
admission to the ICU. Measurement of the effects of a
polymorphism (particularly) in regard to a disease process
like sepsis (a phenomenon driven by a multiple pathway) is
very difficult indeed. Is the polymorphism exerting a direct
effect on the disease process? Does it antagonise or
complement another aspect of the disease process?
Indeed, in polymorphisms occurring in a large proportion
of the population [such as the angiotensin-converting
enzyme (ACE) polymorphism, which may be associated
with a variable outcome from myocardial infarction [6]], the
question has to be asked: if it is so bad, why is it still found
in such a high proportion of the population? The answer
probably is that the negative effect of the gene under one
set of circumstances is more than offset by the beneficial
effect it exerts elsewhere. Another important point is that
ICU practices have at least as much of an effect on
outcome as any polymorphism.
The field of genetic testing is moving at a very fast pace
however. It is now possible to place a set of genetic
markers on a microchip and with the application of a blood
or saliva sample, screen for thousands of genes simultane-
ously. In the not too distant future then, it may well beCritical Care    Vol 4 No 6 Smith
practical to have a quick and reliable test for any number of
sepsis-related polymorphisms. A majority of the audience
indicated that they would be quite happy to use such infor-
mation. Whilst the desire to use every tool against sepsis is
laudable, a moments thought is required. Dr Bion did touch
on the ethical problems of using such information. How
would you tell the patient what the genetic screen revealed?
By definition, the data collected would have major implica-
tions for the children (planned or existing) of the patient.
There are many more tricky ethical obstacles in the way of
the use of such data. As the fields of genetics and molecu-
lar biology have shown, where gene data lead to probabili-
ties and possibilities, the ethical minefield lies in wait.
First presentation of the results of the
international Phase III antithrombin III (ATIII)
trial for severe sepsis, presented by Steven
Opal (Baltimore, USA)
Study objective
To see if replacement therapy with ATIII would achieve a
significant increase in survival rate in patients with sepsis.
Study design
This was a randomised, double blind, multicentre trial. The
expectation was that the placebo group would achieve a
28 day mortality rate of 45%. The study was powered to
detect a 15% reduction in 28 day mortality. A total of
2339 patients entered the trial. They were well matched
for gender and other relevant characteristics and were
randomised to the either the ATIII group (1157 patients)
or the placebo group (1157 patients).
Results
Baseline measurements showed that the ATIII activity was
60% for both groups. After 24h, the placebo group still
showed baseline ATIII activity, but in the ATIII group activ-
ity had risen to about 180%.
At 28 days, mortality in the placebo group was 38.7% and
in the ATIII group, 38.9%. There were no differences
between the two groups for new organ dysfunction or
(ICU) survival. Subgroup analysis revealed no real differ-
ences for any of the analysed parameters but did indicate
a treatment interaction with the use of heparin and ATIII in
concert. Patients not receiving early treatment with
heparin seemed to benefit slightly, with the trend becom-
ing just statistically significant at 90 days.
Black patients seemed to suffer from ATIII treatment but
further analysis indicated that this was probably a ran-
domisation artifact since the black patients allocated to
the ATIII group had higher simplified acute physiology
(SAPS II) scores.
The Karnofsky scores (Table 1) for the two groups
showed no differences at trial entry, or after 28 days. At
56 and 90 days however, there was an indication of
benefit from ATIII treatment for those patients who were
alive and still in hospital for that length of time. There were
no differences in the number of serious adverse events
(multiple organ dysfunction, heart arrest, shock, etc).
One area in which differences were seen between the
two groups was where major or minor bleeding occurred.
In both cases the ATIII group suffered an increased
number of incidences (statistically significant) and this
was associated with a trend towards a worse outcome in
cases of major bleeding. This was exacerbated further by
heparin treatment.
Conclusions
There is no difference in mortality between the placebo and
ATIII groups at 28, 56 or 90 days. With the exception of the
heparin results, subgroup analysis showed no differences.
When the data from the two groups were adjusted to
reflect the SAPS II scores, there was a trend indicating
that ATIII had some (not statistically significant) benefit on
mortality.
Eli Lilly Industrial symposia on ‘The changing
face of sepsis pathogenesis’
Jean-Louis Vincent (Brussels, Belgium), Charles Esmon
(Oklahoma City, USA) and Jean-Francois Dhainaut (Paris,
France) highlighted the role, and the enormous treatment
potential, of activated protein C in sepsis. Research into
treatments for sepsis has recently concentrated on three
drugs: ATIII, tissue factor pathway inhibitor (TFPI) and
recombinant human activated protein C (rhAPC). The
results of the phase III trial with ATIII (above) indicate that
Table 1
The Karnofsky score
100% Normal; no symptoms or signs of active disease
90% Able to carry on normal activity; minor signs or symptoms
of active disease
80% Normal activity with effort
70% Unable to do active work; cares for self
60% Requires occasional assistance
50% Requires considerable assistance and frequent medical
care
40% Disabled; needs special care
30% Hospitalized; death not imminent
20% Hospitalized; critical condition
10% Moribund
0% Deadhttp://ccforum.com/content/4/6/347
this potential avenue of treatment is now no longer a
viable one. The use of exogenous rhAPC to supplement
the decreased levels of activated protein C seen in
patients with severe sepsis looks to have real potential.
Initial work with animal models highlighted the possible
use of rhAPC as a therapeutic agent. The Phase II trial
results were good: trends towards improvements in sys-
temic inflammatory response syndrome (SIRS)-, shock-,
ventilator-, ICU and hospital-free days, as well as a drop in
interleukin (IL)-6 levels (indicative of the anti-inflammatory
properties of rhAPC) were seen. On the basis of these
results, the phase III double blind, randomised, placebo
controlled trial was started. The trial group were to be
infused with 24mg/kg/h rhAPC over 96h. This was a mul-
ticentre trial conducted in 150ICUs on patients with
severe sepsis. The primary end point was 28 day mortality
with secondary end points being the assessment of the
effect of rhAPC on organ dysfunction. The trial was
stopped early when it became apparent that there was
indeed a significant reduction in the 28 day mortality rate
of patients treated with rhAPC. No actual data from the
trial were presented as it still undergoing final analysis.
There was however, this telling quote from Jean-Louis
Vincent: ‘The news is very very good’. This implies that
there is a very significant reduction in mortality when
patients with severe sepsis are given rhAPC. This is espe-
cially interesting since both ATIII and APC act in vivo to
regulate the coagulation system. It would be interesting to
know why the ATIII trial failed and the rhAPC trial looks to
have been far more successful. The data from the rhAPC
trial will be first presented at the 30th International Educa-
tional & Scientific Symposium in San Francisco (10–14
February 2001) and then at the 21st International Sympo-
sium on Intensive Care and Emergency Medicine in Brus-
sels (20–23 March 2001).
Acute respiratory failure: where are we now?
One of the major thematic sessions looked at the outcome
of a number of randomised controlled trials (RCTs) in dif-
ferent aspect of acute respiratory failure (ARF). Dr
Massimo Antonelli (Rome, Italy) began by assessing the
evidence for the use of non-invasive ventilation (NIV) in
patients with hypoxaemic respiratory failure. To date, some
48 studies have been conducted encompassing a total of
1343 patients. The results are encouraging: there appears
to be a clear benefit with the use of NIV. The most recent
of these trials has been reported on in Critical Care
(Paper report: http://ccforum.com/paperview2_page.cfm?
unique_id=5179). These RCTs are all limited by their
small sample size and large scale trials are required before
NIV can be recommended. Dr Antonelli announced his
intention to start a large scale trial to investigate the use of
NIV in patients with hypoxaemic ARF.
Peter Suter (Geneva, Switzerland), presented more sober-
ing news on the results of trials investigating the effective-
ness of pharmacological approaches to the treatment of
ARF. His message was a simple one; nothing has been
shown to be effective. Five anti-inflammatory compounds
have been thoroughly investigated (procysteine, lyso-
phylline, prostaglandin, ketoconazole and N-acetylcysteine
[Paper report: http://ccforum.com/paperview2_page.cfm?
unique_id=1442 ]) and the results have been identical: no
benefit. The use of inhaled nitric oxide, whilst improving
gas exchange in 66% of patients, does not alter outcome
in any significant way (Paper report: http://ccforum.com/
paperview2_page3.cfm?unique_id=2181). Similarly, sur-
factants also improve gas exchange, but again have no
effect on outcome. There was some intriguing news to
report in the use of sedation in ARF. Kress and coworkers
demonstrated that they could wean patients more rapidly
if they interrupted patient sedation on a daily basis [7]
(Paper report: http://ccforum.com/paperview2_page.
cfm?unique_id=5538). This would seem to indicate that
aiming for the minimum necessary sedation, and coupling
that with a daily assessment of the sedation requirement,
is a worthwhile practice. There is the question of which
sedative is best. A meta-analysis by Walder and cowork-
ers (in press) indicates that propofol has a slight advan-
tage over midazolam. Another possible treatment option
may be late phase treatment with steroids (Paper report:
http://ccforum.com/paperview2_page.cfm?unique_id=5578).
Enrollment for the Late Steroid Rescue Study (LaSRS) is
underway, with 75 out of the 200 patients required
already into the study (data from ARDSnet http://www.
ardsnet.org). Dr Suter indicated his belief that a lack of
success with the anti-inflammatory compounds should not
preclude further studies being undertaken. Perhaps
altered dosing and delivery (during the phases of the
disease) may yield results.
Luciano Gattinoni (Milan, Italy) presented data on the via-
bility of proning as a treatment option. Whilst there was no
difference in outcome at either 10 days or discharge from
hospital, proning the patients did result in better oxygena-
tion. Overall, proning is probably not justified as a treat-
ment option, but it may be useful to ‘buy time’ in severe
cases. Of course this may make no material difference,
except to prolong the time to death.
One area where surfactants have had an effect is in
treating respiratory distress syndrome (RDS) in prema-
ture infants. Thomas Wiswell (Philadelphia, USA) sum-
marised the data on over 30 RCTs, the results showing
that surfactant treatment decreases mortality as well as
the severity of RDS. There is no effect on the incidence
of chronic lung disease or neurological damage. There is
currently a debate on whether prophylactic treatment or
rescue therapy is better. Prophylactic treatment does
give a better outcome in infants under 29 weeks, but
then 40–60% of such infants do not need surfactant
treatment.Blood substitutes
The panacea of a single universal blood substitute is
probably an unattainable one. So research on blood
substitutes is proceeding on a number of fronts with the
aim of producing a number of products that are of value
in specific situations.
Charles Wade (Sausalito, USA) presented data on the
use of hypertonic saline dextran (HSD) in trauma
patients as an initial fluid therapy. HSD consists of 7.5%
NaCl in 6% Dextran 70. Initial trials with animal models
gave good survival results but it must be noted that the
trials were small and the population studied was hetero-
geneous. One important result is that HSD has good
volume expansion characteristics: for every 1 ml of HSD
delivered, an expansion of about 1.3ml is achieved. This
is true for both animal and human subjects. In human
subjects, there is a trend for increased survival (not sig-
nificant) at 24h, but more importantly, the survival to
discharge increase is significant. Another important
property is the ability of HSD to increase blood pres-
sure (BP) over the first 30 min (this being the average
transport time for a victim from the trauma scene to the
ER). Dr Wade did speculate as to whether administra-
tion of a hypertonic solution would act to reduce the
magnitude of the inflammatory response, thus account-
ing for the positive survival results, but noted that there
was no direct evidence for this. Patients seem to be
able to tolerate the NaCl loading that occurs upon
administration of HSD. Another concern, that of the
increase in BP breaking up any freshly formed blood
clots particularly in head trauma patients, did not seem
to be realised. HSD seems to be a good candidate for
initial fluid therapy where there is a need to rapidly get
volume into a patient to achieve some measure of stabil-
isation.
William Bickell (Tulsa, USA) elected to argue the case
for the use of ‘fresh full blood’ and a more thoughtful
approach to fluid resuscitation in patients with haemor-
rhagic shock. Drawing on data from the US army (dating
back as far as the first world war) as well as his own
work, he provided evidence that fresh whole blood gives
the best clinical prognosis for recovery. As long as the
BP is approximately 80mmHg, the patient will be rea-
sonably stable and delaying fluid resuscitation can
increase survival rates. This was essentially a plea for
some sense to be applied to the technology. Whilst the
data were quite compelling, there is a problem with the
supply of fresh (less than 72h old) whole blood. Dr
Bickell argued that if supply could meet demand in
WWI then surely it should be possible in the 21st
century. However, it seems unsurprising that when there
are very large numbers of people fighting each other in
a small geographical area there is a ready supply of
blood in large quantities.
There are two basic groups of oxygen substitutes;
haemoglobin based molecules and perflourocarbons.
Jean-Louis Vincent looked at haemoglobin based
oxygen carriers. These may represent a useful tool in
specific applications and may avoid a number of the
known problems with the use of stored blood (viral
infection, the age of the blood, etc). Modern haemoglo-
bin solutions are polymers (haemoglobin cross-linked
with another compound such as diaspirin). These avoid
problems with renal toxicity and short persistence, and
they also have right shifted oxygen dissociation curves.
The haemoglobin can be either human (hard to obtain),
bovine (very easy to obtain but with the potential for
pathogenic contamination) or recombinant (very hard to
manufacture). Oxygen substitutes also have a lower vis-
cosity and a very small particle size (compared to a red
blood cell), leading to better dissemination throughout
the microvasculature. There are a number of potential
problems to be overcome. Could the exposed haemo-
globin be attacked by free radicals? Is the iron loading
that accompanies transfusion with such blood substi-
tutes a problem? Vasoconstriction is an issue, as is
immunosuppression and platelet activation. Clinical
trials with diaspirin cross-linked haemoglobin (DCLHb)
have provided conflicting information, as Maurice Lamy
(Liege, Belgium) explained. In one multicentre trial,
patients who had undergone cardiac surgery received
either packed RBCs or DCLHb. There was no differ-
ence in mortality, but an increased incidence of adverse
events in the DCLHb group [8]. Sloan and coworkers
conducted a trial on patients with severe haemorrhagic
shock and noted a higher mortality rate in the patients
administered DCLHb [9]. Whether this was due to the
administration of DCLHb is not clear. There were base-
line mortality rate differences between the two groups
(the DCLHb group had a higher average Glasgow
Coma Score) and there were more cardiac arrests in
the DCLHb group. Like a number of trials, this was
stopped early due to safety problems. One fact is
apparent, the use of blood substitutes has enormous
potential to bypass many problems associated with
giving blood to critically ill patients. New products are
being developed and a number of these are entering
phase I and II trials. The possibility exists for there to be
a number of products to be available ‘off the shelf’ to
meet the specific requirements of the critically ill patient.
Research into blood substitutes is heading in an excit-
ing direction.
Summary
This is the 20th year of the European Congress. This year
there was exceptional diversity and depth of both educa-
tional and ‘hot-off-the-press’ information for both scientists
and clinicians. Nurses (often under-rated, but a vital part of
the intensive care community) were also accommodated,
with a special section of the congress dedicated to them.
Critical Care    Vol 4 No 6 SmithAs we head off into the new century, all those who
attended the conference have a good idea of what devel-
opments lie ahead in the field of intensive care medicine.
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